Navigation Links
Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer

For patients with high-risk breast cancer treated with radical mastectomy and adjuvant chemotherapy, the addition of radiation therapy leads to better survival outcomes with few long-term toxic effects, according to a 20-year follow-up of a randomized trial, which appears in the January 19 issue of the Journal of the National Cancer Institute.

The British Columbia randomized radiation therapy trial was designed to determine the effect on survival of the addition of locoregional radiation therapy (radiation to the lymph nodes and chest wall) to a course of chemotherapy after radical mastectomy in premenopausal women with lymph node–positive breast cancer. Between 1979 and 1986, 318 patients were randomly assigned to receive no radiation therapy or to receive radiation. A 15-year follow-up found that radiation therapy was associated with improved breast cancer survival but not with overall survival.

In this 20-year follow-up of the British Columbia trial, Joseph Ragaz, M.D., of McGill University Health Center in Montreal, and colleagues found that the chemotherapy and radiation regimen, compared with chemotherapy alone, was associated with improvement in all end points analyzed. This included a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared with chemotherapy alone. In addition, long-term toxic effects, including cardiac deaths, were acceptable for both groups of patients.

"Our results, and those from other groups, confirm that in situations where residual disease remains, adjuvant chemotherapy alone in high-risk breast cancer patients is suboptimal and that the addition of locoregional radiation therapy is important to achieve the highest cure rate," the authors write.

In an editorial, Timothy Whelan, B.M., B.Ch., and Mark Levine, M.D., of the Juravinski Cancer Centre in Hamilton, Ontario, discuss the use of locoregional radiation therapy in breast cancer patients and note that fewer clinicians accept its use in moderate-risk patients. "Because uncertainties continue about the effectiveness of locoregional radiation therapy after mastectomy in moderate-risk patients, we strongly urge that a randomized controlled trial be mounted to resolve these uncertainties," they write.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Adding radiation decreases breast cancer recurrence
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Radiation-killed bacteria vaccine induces broad immune response in mice
4. Radiation-armed robot rapidly destroys human lung tumors
5. Radiation after surgery doubles survival time for some lung cancer patients
6. Radiation therapy combo cures prostate cancer long-term
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Gene Therapy For Parkinsons Disease Moves Forward In Animals
9. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
10. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
11. Discovery Promises Simpler Therapy for Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/18/2019)... ... 17, 2019 , ... Mitotech S.A, a Luxembourg-based clinical-stage biotechnology ... U.S. Phase 3 study VISTA-2 building on positive results of VISTA-1 clinical study ... severe Dry Eye Disease (DED). SkQ1 belongs to the class of cardiolipin peroxidation ...
(Date:12/14/2019)... ... December 11, 2019 , ... Fiberstar, Inc., a global market ... won the 2019 Food Ingredient Europe’s plant-based innovation award. , This prestigious award ... category. Fiberstar who was one of three finalists achieved this award by introducing ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... ... companies today, has launched Subnovii Advanced Plasma Technology for U.S. dermatologists, ... portfolio, Subnovii is the only plasma to employ LF technology – low frequency ...
Breaking Biology News(10 mins):
(Date:1/7/2020)... ... January 06, 2020 , ... EconoFact, ... The Fletcher School at Tufts University, is pleased to announce that it was ... be administered by Tufts University, and will help to expand the scope, exposure ...
(Date:12/31/2019)... Md. (PRWEB) , ... December 31, 2019 , ... ... ground in expanding its pharmaceutical product development lab in Maryland. Emphasis ... the increased size and expanded capabilities, Vici Health Sciences will be well positioned ...
(Date:12/27/2019)... ... December 27, 2019 , ... Leak Detection Associates ... the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries is excited to celebrate ... acquisition by CLJ Holdings in February, 2019, a comprehensive and aggressive reorganization plan ...
(Date:12/18/2019)... ... December 17, 2019 , ... ... clearance for reprocessing Electrophysiology (EP) devices since the company’s inception in 2016. This ... and SterilMed (a Johnson & Johnson company) have received 2 and 4 EP ...
Breaking Biology Technology: